Thompson Davis & CO. Inc. Acquires 6,530 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)

Thompson Davis & CO. Inc. increased its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 44.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 21,130 shares of the company’s stock after acquiring an additional 6,530 shares during the quarter. GeneDx makes up approximately 1.0% of Thompson Davis & CO. Inc.’s holdings, making the stock its 8th biggest holding. Thompson Davis & CO. Inc. owned 0.08% of GeneDx worth $1,624,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of WGS. MCF Advisors LLC raised its holdings in shares of GeneDx by 107.7% during the fourth quarter. MCF Advisors LLC now owns 351 shares of the company’s stock valued at $27,000 after buying an additional 182 shares during the last quarter. Global Retirement Partners LLC bought a new stake in shares of GeneDx during the fourth quarter valued at approximately $28,000. Rhumbline Advisers raised its holdings in shares of GeneDx by 5.5% during the fourth quarter. Rhumbline Advisers now owns 19,750 shares of the company’s stock valued at $1,518,000 after buying an additional 1,021 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of GeneDx by 10.6% during the fourth quarter. Principal Financial Group Inc. now owns 15,751 shares of the company’s stock valued at $1,211,000 after buying an additional 1,511 shares during the last quarter. Finally, Palumbo Wealth Management LLC raised its holdings in shares of GeneDx by 22.8% during the fourth quarter. Palumbo Wealth Management LLC now owns 8,303 shares of the company’s stock valued at $638,000 after buying an additional 1,542 shares during the last quarter. Institutional investors own 61.72% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Kevin Feeley sold 1,137 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $76.37, for a total value of $86,832.69. Following the completion of the transaction, the chief financial officer now owns 24,731 shares of the company’s stock, valued at approximately $1,888,706.47. This trade represents a 4.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Katherine Stueland sold 1,657 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $78.48, for a total transaction of $130,041.36. Following the completion of the transaction, the chief executive officer now directly owns 3,937 shares of the company’s stock, valued at $308,975.76. This represents a 29.62 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 127,584 shares of company stock worth $11,336,520. 27.30% of the stock is owned by insiders.

GeneDx Trading Down 5.7 %

GeneDx stock opened at $95.83 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. The firm has a market cap of $2.63 billion, a price-to-earnings ratio of -48.89 and a beta of 2.01. GeneDx Holdings Corp. has a 1 year low of $6.79 and a 1 year high of $115.60. The firm’s 50 day moving average price is $79.05 and its two-hundred day moving average price is $62.88.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.66. The firm had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. On average, research analysts predict that GeneDx Holdings Corp. will post 0.52 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently commented on WGS. Craig Hallum raised their price objective on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. TD Cowen raised their price objective on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, January 7th. Wells Fargo & Company raised their price objective on shares of GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 30th. Finally, The Goldman Sachs Group raised their price objective on shares of GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $72.33.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.